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Abstract 
 
Background:  Rheumatoid arthritis is a chronic, progressive autoimmune disease that 
erodes joint synovium and affects other body organs and vasculature.  While current 
therapies, designed to address the impact of rheumatoid arthritis on joints, have been 
shown to be of benefit, the disabling and progression nature of the disease remains.  In 
addressing the cardiovascular complications of this disease, providers may have stumbled 
upon another medication, a cholesterol lowering medication known as statins, which may 
prove beneficial for patients by decreasing inflammation and slowing disease 
progression.  This review will examine the impact of statin medications of rheumatoid 
arthritis disease progression, as assessed by the DAS28.  
 
Method:  An exhaustive search of the literature was conducted in Medline (Ovid) and 
Web of Science using the following search terms: rheumatoid arthritis, HMG Co-A 
inhibitor, statin, “severity of illness index”, disease progression, and treatment outcome.  
A search in CINAHL required the additional keywords anticholesteremic agents and 
antilipemic agent.  Studies that assessed the effect of statin medications on DAS28, an 
index used to assess rheumatoid arthritis severity, were included.  Studies were further 
limited to human subjects, adults, and English language.  
 
Results:  A total of 132 results were found, 17 of which were further screened using the 
eligibility criteria, and five studies qualified for this systematic review.  Four studies are 
randomized clinical trials, including one crossover study, and one is a prospective cohort 
study.  In all studies, statin medications were shown to improve specific inflammatory 
markers (such as swollen joint counts, tender joint counts, CRP, and ESR), however, only 
three studies demonstrated their improvement of the DAS28 itself. 
 
Conclusion:  The results of this systematic review demonstrate a trend of decreased 
inflammation in rheumatoid arthritis patients relatable to statin therapy; however, the 
picture remains unclear as to the improvement in rheumatoid arthritis disease progression 
with adjuvant statin use.  
 
Keywords:  rheumatoid arthritis, DAS28, disease activity, disease progression, HMG-
CoA inhibitor, severity of illness, statin, treatment outcome 
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The Effect of HMG-CoA Inhibitors (Statins) on Rheumatoid Arthritis Disease 
Progression:  A Systematic Review 
 
BACKGROUND 
 Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized by 
synovitis and leading to deformity and chronic disability. It may also affect organs, as 
well as vasculature.  Currently, treatment for RA is based primarily in disease-modifying 
anti-rheumatic medications (DMARDs), which include TNF-alpha blockers, immune 
modulators, anti-folates, and purine synthesis inhibitors.  These medications have been 
shown to slow RA disease progression, improve function, and decrease incidence of 
acute flares, and one particular DMARD, hydroxycholorquine, originally developed to 
treat malaria, has been shown to also improve lipid profiles in RA patients.1 Adjunct 
therapy aims to address acute flares and disability by treating inflammation and pain 
using steroids and non-steroidal anti-inflammatory drugs (NSAIDs).  
 Unfortunately, current therapies, while systemically beneficial, do not target 
extraarticular manifestations of RA.  Such manifestations include optic scleritis, 
pulmonary nodules, and most concerning, vasculitis.  According to studies by del Rincon 
et al2 and Avina-Zubieta et al,3 in controlling for cardiovascular risk factors, patients with 
RA are at an increased risk of cardiovascular events compared to the general population.  
It is thought that the low-grade systemic inflammation of RA contributes to unexplained 
vascular disease in RA patients, however the pathophysiology behind such systemic 
inflammation remains in question.  Some scholars believe it to be secondary to oxidative 
stress, while others attribute it to endothelial dysfunction, both theories supporting the 
notion that a biological stressor or injury leads to development of vasculitis and 
subsequent atherosclerotic changes.  
 7 
 Regardless of the underlying pathophysiology, to help decrease cardiovascular 
manifestations and complications, traditional cardioprotective therapies have been 
implemented in RA patients as adjuvant therapy to DMARDs, prednisone, and NSAIDs.  
One such cardioprotective therapy is the medication class 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase inhibitors (HMG-CoA inhibitors), also known as statins, which 
are touted for both their lipid lowering profile and also for what has been deemed an 
“anti-inflammatory” effect on endothelium.  The role of statins as a means to control 
lipids and decrease cardiovascular risk has been well studied and shown to be significant. 
Results from the PROVE IT-TIMI22,4 MIRACL,5 JUPITER,6 PRINCE,7 and 
AFCAPS/TexCAPS8 trials provide good evidentiary support for improvement in 
cardiovascular risk and decrease in CRP levels with statin use.  However, the extent to 
which the pleiotropic effects of statins extend beyond the vessel wall is unclear.   
 Furthermore, there is a school of thought that purports the “anti-inflammatory” 
effect of statins is, in fact, low-density lipoprotein (LDL)-dependent, meaning any LDL-
lowering agent would provide similar anti-inflammatory benefits.  If anti-inflammatory 
effects are both LDL-dependent and independent, implementation of statin therapy may 
prove to be dually beneficial in an adult RA patient with active disease by addressing 
both dyslipidemia and the low-grade systemic inflammation that further compromises 
cardiovascular health.  
 To better understand this association, a relationship between statin use and 
decreased systemic inflammation in RA patients must be determined.  Ideally, either 
radiologic studies or a laboratory test would be used.  However, comparison of hand/feet 
radiographs in relation to statin therapy has not been studied and C-reactive protein 
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(CRP) and erythrocyte sedimentation rate (ESR), both sensitive markers of inflammation, 
are easily influenced by many different biological and environmental factors.  Thus, a 
different approach is required.  The disease activity score, DAS28, is calculated at each 
visit using the patient’s ESR, rating of health on a visual analog scale, and also the 
patient’s number of tender and swollen joints (out of 28).  According to the National 
Rheumatoid Arthritis Society,9 a DAS28 > 5.1 demonstrates active disease, a DAS28 < 
3.2 demonstrates well controlled disease, and a score < 2.6 qualifies for remission.  If the 
DAS28 score is > 3.2 or trends higher over time, this may lead the provider to adjust 
current therapies to help slow disease progression.   
 As such, comparison of the DAS28 from RA patients with and without adjuvant 
statin treatment will demonstrate if statins provide a benefit to RA disease progression.  
 The use of statins will specifically address certain cardiovascular manifestations 
of RA, such as vasculitis and dyslipidemia, which significantly compromise RA patient 
longevity.  Furthermore, as adjuvant therapy to traditional RA treatment, statins may both 
slow disease progression, and reduce use or dose of the traditional medications, thus 
lessening occurrence of related adverse drug reactions (ADRs) such as gastrointestinal 
bleed, osteomalacia, increased susceptibility to infection, and disruption of autologous 
cortisone production. 
 Additionally, the cost of DMARDs is very high and this year atorvastatin, Lipitor, 
will be available in generic form, making this adjuvant therapy cost effective in both the 
short term (monthly co-pay cost) and long term (cost of disease and disability over time). 
 Of note, statins can further be broken down into those that are lipophilic or 
hydrophilic.  While all statin medications carry the risk of elevated liver function tests, 
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myalgias, and, rarely, rhabdomyolysis, lipophilic statin medications such as atorvastatin 
(Lipitor) and simvastatin (Zocor) are associated with a higher incidence of myalgias, a 
smaller reduction in LDL, and a smaller increase in HDL.  Hydrophilic statin medications 
such as rosuvastatin (Crestor) and pravastatin (Pravachol) have better lipid profiles and 
fewer reports of myalgias.  This paper will not differentiate the different classes and will 
consider the statin family as a whole.  
 
METHODS  
Literature Search 
A systematic search was performed in the following databases:  Medline, 
CINAHL, and Web of Science.  Keywords included:  rheumatoid arthritis, HMG Co-A 
inhibitor, statin, “severity of illness index,” disease progression, and treatment outcome.  
In CINAHL, the search required the additional keywords anticholesteremic agents and 
antilipemic agent. Studies were limited to human studies and English language. Editorials 
and meeting abstracts were not included.  The last search was performed in April 2012. 
Articles were evaluated for validity using the GRADE criteria.10 Based on the quality of 
evidence, articles were categorized as: high, medium, low, and very low.  Table I 
summarizes the GRADE system as applied. 
Inclusion and Exclusion Criteria 
All randomized, placebo- or active-controlled double-blind clinical trials meeting 
criteria of adult patients with active RA (as defined by EULAR criteria)11 on stable 
DMARD dosing and without a medical history significant for hypertension, dyslipidemia, 
artery disease, myocardial infarction, diabetes, allergy to statin, or elevated liver function 
 10 
tests were included.  All trials had a minimum of nine patients in each study group. 
Studies were included if either the primary or secondary outcome addressed the impact of 
statin use on DAS28.  The intervention was considered to be statin and the control to be 
placebo.  Trials and studies were included if they allowed DMARD, steroid, and NSAID 
treatment during the trial period, however, DMARD dosing had to be maintained at the 
same dose and rate in the three months prior to study inception.   
Exclusion criteria included DMARD instability before study implementation, 
secondary analysis of original data, and use of the Markov model to expand existing 
study data gathered in six months out to ten years for cost analysis.  Also, studies 
addressing only cardiovascular events and outcomes were excluded and studies that 
collected data sufficient to calculate DAS28 (ESR, VAS, and joint count) but that did not 
do so were also excluded.  Of note, studies were not excluded if they measured highly 
sensitive-CRP (hs-CRP) rather than CRP, as hs-CRP is a measurement of CRP at lower 
concentrations.12  
 
RESULTS   
 Once duplicates were removed, 132 results remained, 17 of which were further 
screened using the eligibility criteria.  Five studies are reviewed.  (See Figure I.)  Four are 
randomized-controlled trials,13-16 one of which is unblinded16 and one of which is a 
crossover study,14 with the fifth study being a prospective cohort observational study.17 Two 
studies took place in the United States,13, 15 one in Japan,17 one in Britain,14 and one in 
Egypt.16 Study dates range from 200413 to 2011.16 All studies are presented in Table I with 
summary of findings presented in Table II.  
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Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo 
controlled trial 
McCarey et al (2004) 
The 2004 TARA trial by McCarey et al13 assessed 116 RA patients on stable RA 
treatment divided into 58 patients receiving 40mg atorvastatin (trade name Lipitor 
manufactured by Pfizer) and 58 patients receiving a placebo.  The primary endpoint was 
change in DAS28 with secondary endpoints of change in ESR, CRP, lipid profile, and 
plasma viscosity.  Patients were computer randomized by an independent administrator at 
an off-site location.  Both patients and doctors were blinded to group allocation.  
Standard RA treatment included DMARDs, NSAIDs, and steroids was allowed. DMARD 
dose was maintained at a steady level both in the three months before study inception and 
through study duration.  With the exception of the four weeks before clinical assessment, 
intramuscular and intraarticular steroid injections were allowed.  Exclusion criteria 
included: diabetes, familial dyslipidemia, current lipid lowering therapy, oral prednisone 
> 10mg/day, significant renal disease, and elevated liver enzymes or creatinine kinase 
found to be twice the normal limit at baseline.  Smoking was not an exclusion criteria, 
however, the number of patients that smoke was prognostically similar between groups.  
Also, with the exception of methotrexate use, the groups were prognostically similar.13 
Follow-up was maintained for six months with five withdrawals in the statin 
group (one lost to follow-up, three with ADRs, and one with pregnancy) and 13 
withdrawals in the control group (four lost to follow-up, two with ADRs, seven for 
inefficacy of treatment).  Authors report atorvastatin to be well-tolerated in the 
intervention study population, with similar frequency in reported ADRs between study 
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groups. There was no significant elevation in LFTs or muscle abnormalities detected or 
reported by those taking atorvastatin.  Dropouts were analyzed in the groups to which 
they were assigned under the assumption of no change in baseline laboratory or 
assessment values.   
DAS281 in the statin group decreased by 0.50 compared to a 0.03 increase in the 
control group (p=0.004).  ESR† decreased by 5.03mm/h in the statin group versus a 
1.91mm/h increase in the placebo group (p=0.005).  CRP† also decreased in the statin 
group by 0.46 log mg/L, but increased in the control group by 0.12 log mg/L (p<0.0001).  
Swollen joints decreased by 2.69 in the statin group [95% confidence interval (-3.81) –  
(-1.57)]2 versus a decrease of 0.53 in the control group [95% CI (-1.59) – 0.52], 
p=0.0058.  Additionally, tender joints decreased by 1.21 [95% CI (-3.28) – 0.86] and 
increased by 0.38 [95% CI (-1.16) – 1.92] in the statin and control groups, respectively 
(p=0.22).13  
Regarding changes in cholesterol, atorvastatin resulted in a decrease in total 
cholesterol by 1.48mmol/L [95% CI (-1.73) – (-1.23)], a decrease in triglycerides by 
0.24mmol/L [95% CI (-0.34) – (-0.14)], a decrease in LDL by 1.40mmol/L [95% CI  
(-1.63) – (-1.17)], and an increase in HDL by 0.03mmol/L [95% CI (-0.03) – 0.09].  The 
control group demonstrated a decrease in total cholesterol by 0.01mmol/L [95% CI  
(-0.14) – 0.12], an increase in triglycerides by 0.07mmol/L [95% CI (-0.04) – 0.18], a 
decrease in LDL by 0.07mmol/L [95% CI (-0.23) – 0.10], and a decrease in HDL by 
0.04mmol/L [95% CI (-0.10) – 0.02].  Statistically, differences in total cholesterol, 
                                                        1 See Table II for 95% confidence interval 2 For all results, where necessary, standard deviations were converted to 95% confidence intervals [95% CI] 
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triglycerides, and LDL between the intervention group and control group were p<0.0001. 
The difference in HDL was p=0.097.13  
To account for the higher incidence of methotrexate use by patients in the 
atorvastatin group, patients within this group were further analyzed with a comparison 
showing a difference of 0.19 in DAS28 [95% CI (-0.31) – 0.69, p=0.46], 1.72mm/h in 
ESR [95% CI (-5.06) – 8.51, p=0.61], and 0.12 log mg/L in CRP [95% CI (-0.24) – 0.49, 
p=0.51] between those in the statin group taking methotrexate and those in the statin 
group using a different DMARD.13 
The study concluded that statins have a beneficial impact on RA by decreasing 
ESR, CRP, tender joint counts, swollen joint counts, and DAS28.  Also, the study 
demonstrated that those in the intervention group using methotrexate had similar results 
to those in the same group using a different DMARD.13 
Under a “conflict of interest” statement, the study notes two principal authors 
received educational grants from Pfizer, the manufacturer of atorvastatin, to fund ex-vivo 
analyses included in the report and several authors received travel grants or honoraria 
from Pfizer in the three years before study inception.  The study further states that there is 
no employment, consultant, stock ownership, paid expert testimony or patent application 
relationships between study authors and Pfizer.13 
Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness 
and Improve Endothelial Function in Rheumatoid Arthritis 
Maki-Petaja et al (2007) 
In 2007, Maki-Petaja et al14 performed a randomized, double-blind cross-over 
study to assess the difference between ezetimibe (available only under trade name Zetia) 
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and simvastatin (available both as generic and under trade name Zocor), both of which 
are manufactured by Merck, on inflammation, disease activity, and endothelial function 
in patients with RA.  Twenty patients with active RA from Addenbrooke’s Hospital 
rheumatology clinics and twenty age- and gender-matched control patients were 
recruited.  Exclusion criteria included: cardiovascular disease, untreated hypertension, 
diabetes, dyslipidemia, renal disease, and current smokers.  Study design consisted of 
four parts: a two-week placebo run-in, followed by a six-week exposure to simvastatin 
20mg/day or ezetimibe 10mg/day, then a six-week wash-out period, and ending with a 
six-week exposure to simvastatin 20mg/day or ezetimibe 10mg/day, whichever 
medication was not administered during the first exposure.  Exposure to medications was 
randomly assigned.  There is no mention of how medications were dispensed or if 
packing was similar.  The length of the washout period was calculated using a custom 
hypothesis test and found to be six-weeks in order to prevent carry-over effects of the 
previous medication.14  
After the completion of each cross-over stage (the end of week 2, week 8, week 
14, and week 20), fasting lipid profile, blood glucose, ESR, rheumatoid factor, hs-CRP, 
and oxidized low-density lipoprotein (ox-LDL) were drawn and DAS28 was calculated 
using number of swollen and tender joints (out of 28 assessed joints), ESR, and patient-
assessed VAS of overall well-being.  Results demonstrated a reduction in DAS28† from 
4.41 at baseline to 3.86 after ezetimibe and from 4.65 at baseline to 3.98 after simvastatin 
(overall significance p<0.002 with significance between drugs of p=0.7).  ESR† 
decreased from 18.2mm/h at baseline to 12.9mm/h after ezetimibe and from 18.6mm/h at 
                                                        † See Table II for 95% confidence interval 
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baseline to 13.8mm/h after simvastatin (overall p-value <0.006 and difference between 
drugs p=0.9).  Ezetimibe decreased hs-CRP† from 14.2mg/L at baseline to 8.8mg/L, 
while simvastatin decreased hs-CRP from 15.3mg/L at baseline to 10.3mg/L (statistical 
significance p=0.002 overall and p=0.9 between drugs).  
Mean total cholesterol decreased from 5.3mmol/L at baseline [95% CI 3.3 – 7.3] 
to 4.7mmol/L after ezetimibe [95% CI 2.7 – 6.7, p<0.001] and from 5.4mmol/L at 
baseline [95% CI 3.6 – 7.2] to 4.1mmol/L after simvastatin [95% CI 2.7 – 5.5, p<0.001], 
with a statistical significance between drugs at p<0.001.  LDL was reduced from 
3.08mmol/L at baseline [95% CI 1.24 – 4.92] to 2.53mmol/L after ezetimibe [95% CI 
0.65 – 4.41, p<0.001] and from 3.18mmol/L at baseline [95% CI 1.62 – 4.74] to 
1.95mmol/L after simvastatin [95% CI 0.83 – 3.07, p<0.001], statistical difference 
between drugs p=0.001.  Triglycerides were reduced from 1.5mmol/L at baseline [95% 
CI 0.1 – 2.9] to 1.3mmol/L after ezetimibe [95% CI (-0.1) – 2.7, p<0.025] and from 
1.4mmol/L at baseline [95% CI 0.4 – 2.4] to 1.3mmol/L after simvastatin [95% CI (-0.3) 
– 2.9], overall p=0.02 and difference between drugs of p=0.8.  HDL increased from 
1.59mmol/L at baseline [95% CI 0.49 – 2.59] to 1.65mmol/L with ezetimibe [95% CI 
0.51 – 2.79] and from 1.62mmol/L at baseline [95% CI 0.60 – 2.64] to 1.65mmol/L with 
simvastatin [95% CI 0.79 – 2.51], statistical significance of p=0.4 overall and p=0.7 
between drugs.   
Tender joint count decreased from 8.45 at baseline [95% CI (-4.11) – 21.01] to 
7.30 after ezetimibe [95% CI (-7.44) – 22.04] and from 10.20 at baseline [95% CI (-6.46) 
– 26.86] to 7.4 with simvastatin [95% CI (-7.14) – 21.94], p=0.03 overall, p=0.3 between 
                                                        † See Table II for 95% confidence interval 
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medications.  Swollen joint count decreased from 5.50 at baseline [95% CI (-3.38) – 
14.38] to 4.30 with ezetimibe [95% CI (-8.58) – 17.18] and from 5.45 at baseline [95% 
CI (-5.29) – 16.19] to 4.65 with simvastatin [95% CI (-7.35) – 16.65], overall statistical 
difference of p=0.4 and statistical difference between drugs of p=0.8.  Visual analog scale 
decreased from 33.85 at baseline [95% CI (7.37) – 75.07] to 33.80 with ezetimibe [95% 
CI (-8.84) – 76.44] and from 38.15 at baseline [95% CI (-6.95) – 83.25] to 36.85 with 
simvastatin [95% CI (-5.35) – 79.05], overall statistical difference and difference between 
drugs of p=0.8.14 
Adverse drug reactions, losses to follow-up, and other medical complications 
were not provided.  
Study authors believe their data reveals a similar decrease in inflammation, and 
DAS28, with ezetimibe and simvastatin and question if this is a result of a small sample 
size or whether the mere reduction of LDL is anti-inflammatory in and of itself.14 
It is noted in the study that the principal author’s doctoral studies were funded by 
GlaxoSmithKline, a large pharmaceutical company, and a co-author received an 
unrestricted grant from Pfizer to develop a website promoting cardiovascular risk 
reduction.14 
Effects of High-dose Atorvastatin on Antiinflammatory Properties of High Density 
Lipoprotein in Patients with Rheumatoid Arthritis: A Pilot Study 
Charles-Schoeman et al (2007) 
Charles-Schoeman et al15 investigated the effects of high-dose atorvastatin 
(Lipitor) on certain lipid levels of RA patients.  This 2007 study randomly assigned 
twenty patients with active RA to receive 80mg of atorvastatin (n=11) or a placebo (n=9) 
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for 12 weeks.  Both patients and physicians are blinded to group allocation. Patients were 
recruited from the rheumatology clinic at University of California, Los Angeles (UCLA). 
Primary outcomes of this study were changes in inflammatory properties of HDL, as 
assessed by cell-free assay (CFA), and hs-CRP with atorvastatin therapy.  Secondary 
outcomes included:  change to DAS28, tender or swollen joint counts, patient pain 
assessment using VAS, ESR, and lipid levels.  Patients’ anti-rheumatic medications were 
continued and study exclusion criteria included:  changes to anti-rheumatic therapy 
within three months, pregnancy, lactation, previous qualification for lipid-lowering 
therapy, hepatic disease, elevated liver function tests, and treatment with 
hydroxychloroquine in the three months before study enrollment.  Groups were 
prognostically similar at baseline with the exception of hs-CRP, which was higher in the 
atorvastatin group (10.4mg/L) than the placebo group (3.2mg/L), p=0.04.15 
Patients followed-up at weeks 0, 3, 6, 12, and 18, and fasting blood tests 
performed for lipid analysis and liver function tests at weeks 0, 6, and 12 weeks.  Hs-
CRP, ESR, interleukin 6, and tumor necrosis factor-alpha were assessed at weeks 0 and 
12.  Changes in outcomes were recorded, however, the study did not provide standard 
deviations or 95% confidence intervals for the results. Instead, the range of values was 
given.15  
Mean differences in outcomes after 12 weeks demonstrated a decrease in DAS* 
by 0.78 in the placebo group and by 0.80 in the atorvastatin group (p=0.98), a decrease in 
ESR* of 0.0mm/h and 2.7m/h in the placebo and statin groups, respectively, (p=0.64), 
and an increase in hs-CRP* with placebo by 4.8mg/L versus a decrease in hs-CRP of 
                                                        * See Table II for range of values. 
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5.6mg/L in the statin group (p=0.14).15   
Total cholesterol increased by 1.0mg/dL with placebo group [range (-32) – 57], 
compared with a decrease of 63.1mg/dL in the statin group [range (-106) – (-40)], 
p<0.0001.  LDL increased by 0.8mg/dL in placebo group [range (-23) – 45] versus a 
decrease by 57.9mg/dL with statins [range (-93) – (-37)], p<0.0001.  In the placebo 
group, triglycerides increased by 4.5mg/dL [range (-53) – 101] and HDL decreased by 
0.8mg/dL [range (-0.9) – 7.0], compared to a decrease in triglycerides of 16.8mg/dL 
[range (-86) – 22] and a decrease in HDL of 2.0mg/dL [range (-14) – 16] in the statin 
group, p=0.33 and p=0.76, respectively.15  
Number of tender joints decreased by 10.1 in the placebo group [range (-34) – 32] 
and by 12 in the statin groups [range (-37) – 1.0], p=0.8. Swollen joint counts decreased 
by 3.8 in placebo group [range (-7.0) – 5.0] and by 0.4 in the statin group [range (-9.0) – 
20], p=0.11.15   
One patient from each group was lost to follow-up, one due to transportation 
(placebo), and the other due to concern of mild LFT elevation (atorvastatin).15 
Pfizer provided Atorvastatin.  Study authors include Dr Alan Fogelman, chair of 
the department of medicine at UCLA and founder of Bruin Pharma, a company with a 
specialized focus on medications that enhance the anti-inflammatory properties of HDL.  
Another study author is also a principal and stockholder at Bruin Pharma.15 
Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in 
Rheumatoid Arthritis 
El-Barbary (2011) 
In a 2011 study, El-Barbary et al16 investigated the effect of atorvastatin on 
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inflammation and vascular risk factors in RA patients. 30 DMARD-naive, prognostically 
similar patients with an RA diagnosis received within one year of study start were 
randomly divided into two groups:  Group 1 (n=15) received methotrexate 
0.2mg/kg/week plus prednisone 10mg/day, while Group 2 (n=15) received the same 
therapy plus atorvastatin 40mg/day.  For further control, 10 healthy age- and gender-
matched individuals were enlisted for comparison.  Over six months, study investigators, 
unblinded to group allocation, assessed DAS28, CRP, lipid profile, endothelial 
dysfunction, and several other biochemical markers.16 
Study exclusion criteria included:  conditions affecting lipid profile, endothelial 
dysfunction, and arterial stiffness, conditions such as diabetes, hypothyroidism, obesity, 
current smokers, familial dyslipidemia, history of heart attack within six months of study 
start date, cancer, and current use of anticholesteremic medications, beta blockers, 
hormone therapy, and vitamin E.  Methotrexate dose remained stable throughout study 
duration, however, providers were allowed to use their discretion and taper prednisone in 
accordance with patient improvement.  In both groups, steroids were held in the four 
weeks leading up to clinical and laboratory assessment.16 
Analysis of data revealed a decrease in DAS28† in Group 1 (methotrexate and 
prednisone only) from 6.19 at baseline to 5.27 with treatment compared to a decrease of 
6.09 at baseline to 3.9 with treatment in Group 2 (methotrexate and prednisone plus 
atorvastatin), p<0.001.  ESR† decreased from 56.93mm/h at baseline to 43.60mm/h in 
Group 1 and from 58.33mm/h at baseline to 26.73mm/h in Group 2, p<0.001.  CRP† 
decreased from 33.06mg/L at baseline to 19.73mg/L in Group 1 and from 31.46mg/L at 
                                                        † See Table II for 95% Confidence interval 
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baseline to 7.20mg/L in Group 2, p<0.001.16   
In Group 1, total cholesterol increased from 224.66mg/dL at baseline [95% CI 
162.42 – 286.90] to 235.66mg/dL after treatment [95% CI 173.8 – 297.52, p<0.05], LDL 
decreased from 142.33mg/dL [95% CI 93.51 – 191.15] to 140.40mg/dL [95% CI 89.0 – 
191.8], triglycerides decreased from 137.33mg/dL [95% CI 42.71 – 231.95] to 
137.13mg/dL [95% CI 43.57 -230.69], and HDL increased from 44.06mg/dL [95% CI 
25.82 – 62.30] to 51.73mg/dL [95% CI 31.63 – 71.83, p<0.001].  In Group 2, total 
cholesterol decreased from 228.13mg/dL at baseline [95% CI 204.63 – 251.63] to 
191.80mg/dL after treatment [95% CI 166.26 – 217.34, p<0.001], LDL decreased from 
142.66mg/dL [95% CI 94.0 – 191.32] to 120.26mg/dL [95% CI 91.98 – 148.54, 
p<0.001], triglycerides decreased from 126.93mg/dL [95% CI 62.99 – 190.87] to 
96.60mg/dL [95% CI 59.22 – 133.98, p<0.001], and HDL increased from 41.60mg/dL 
[95% CI 19.9 – 63.3] to 60.07mg/dL [95% CI 41.31 – 78.83, p<0.001].16   
In Group 1, swollen joint counts decreased from 6.73 at baseline [95% CI 2.05 – 
11.41] to 4.20 after treatment [95% CI 0.64 – 7.76, p<0.001] and tender joint counts from 
11.0 [95% CI 5.82 – 16.18] to 7.20 [95% CI 3.98 – 10.42, p<0.001]. In contrast, in Group 
2, swollen joints decreased from 6.06 at baseline [95% CI 0.86 – 11.26] to 1.53 after 
treatment [95% CI (-0.13) – 3.19, p<0.001] and tender joint counts decreased from 11.13 
[95% CI 4.87 – 17.39] to 3.8 [95% CI 1.16 - 6.44, p<0.001].  In Group 1, VAS improved 
from 54.66 at baseline [95% CI 27.56 – 81.76] to 42.00 [95% CI 20.36 – 63.64, p<0.001] 
and morning stiffness lasted at 77.0 minutes at baseline [95% CI 5.42 – 148.58] and 
dropped to 59.33 minutes after treatment [95% CI (-8.25) – 126.91, p<0.001] versus 
Group 2, in which VAS improved from 56.0 at baseline [95% CI 26.44 – 85.56] to 21.0 
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after treatment [95% CI 7.28 – 34.72, p<0.001] and morning stiffness improved from 
86.0 minutes at baseline [95% CI (-3.6) – 175.6] to 19.33 minutes after treatment [95% 
CI (-1.99) – 40.65, p<0.001]. Statistical significance between drugs for above 
measurements is p<0.001.16 
Authors report atorvastatin to be well-tolerated with mild gastrointestinal adverse 
events arising in both groups equally. There was no significant elevation in liver function 
or muscle abnormalities for those taking atorvastatin. 
While the study does report that 12 of 15 patients in Group 1 and 11 of 15 patients 
in Group 2 received oral steroids between 5-10mg per day, the study reports neither the 
number of patients who decreased steroid dose or frequency nor the amount of such 
decreases.  Also, study authors do not mention any conflicts of interest in terms of 
funding or associations with pharmaceutical companies.16 
Beneficial Action of Statins in Patients with Rheumatoid Arthritis in a Large 
Observational Cohort 
Okamoto et al (2007) 
A prospective cohort observational study performed by Okamoto et al17 in 2007 
analyzed possible benefits of statins in RA disease activity.  Using data from the seventh 
phase of the cohort, containing 4152 patients with active RA, authors examined the 
difference in DAS28, CRP, ESR, Pain VAS, physician VAS, swollen joint counts, and 
tender joint counts between those taking statins (n=279) and those who were not 
(n=3873).  Data was collected at bi-annual visits, one in both the fall and spring, and 
consisted of patient questionnaires, physician assessment, and laboratory data.  DAS28 
was calculated using a method developed by Prevoo et al.18 The groups were noted to be 
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prognostically dissimilar, the statin group being older (mean age 64 in statin group versus 
58 in control group) and having a longer disease duration (mean duration of 13 years in 
statin group compared to almost 12 years in control group). No p-values or confidence 
intervals were given to support this statement.17 
Results did not demonstrate an improvement in DAS28† (mean value of 3.45 in 
statin group versus 3.57 in control, p>0.05), however they did demonstrate improvement 
in CRP† (mean value of 0.85mg/dL in statin group versus 1.24mg/dL in control, 
p<0.0001). Additionally, pain VAS improved {mean of 27.32 in statin group [95% CI (-
23.36) – 78.0) versus a mean of 31.13 in control group [95% CI (-22.65) – 84.91], 
p<0.05)}, physician assessment improved {(mean of 12.59 in statin group [95% CI (-
11.61) – 36.79] compared to 15.89 in control group [95% CI (-14.23) – 46.01], 
p<0.001)}, and joint counts also improved {(mean swollen joint count of 1.80 [95% CI (-
3.92) – 7.52] and mean tender joint count of 2.32 [95% CI (-5.88) – 10.52] in statin group 
versus mean swollen joint count of 2.55 [95% CI (-4.45) – 9.55] and tender joint count of 
2.87 [95% CI (-6.99) – 12.73] in control group, p<0.0001 and p<0.05, respectively)}. 
Changes in ESR, total cholesterol, LDL, triglycerides, or HDL were not recorded.17 
To account for the increased use of steroids in the statin group, the results were 
further analyzed to compare results between those using low-dose (0-1mg prednisone per 
day), medium-dose (1-5mg prednisone per day), and high-dose steroids (>5mg 
prednisone per day).  While the authors noticed a positive relationship between high-dose 
steroid use and serum cholesterol, they also noted that comparison within steroid dose 
groups showed those taking statins to have lower measures of disease activity (CRP, joint 
                                                        † See Table II for 95% Confidence interval 
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counts, pain VAS, and physician VAS) while demonstrating no difference in DAS28.17 
Authors note the research is supported by a grant from 33 different 
pharmaceutical groups, including Wyeth, Novartis, Pfizer, AstraZeneca, Aventis, and 
GlaxoSmithKline.  The authors do not note an association or relationship between the 
companies and the authors themselves.17 
 
DISCUSSION  
While all studies13-17 show statins to improve individual markers of inflammation, 
the picture remains mixed as to the effect of statins on RA disease progression.  Three of 
the five studies13, 14, 16 analyzed demonstrated a statistically significant improvement 
(p=0.004, p=0.002, and p<0.001, respectively) in DAS28 with adjuvant statin use, while 
the other two studies demonstrated either a statistically insignificant improvement 
(p>0.05)15 or almost no statistical difference between the placebo and statin (p=0.98).17 
While not all studies demonstrated a statistically significant decrease in DAS28 
with statin use, they all showed improvement in one or more individual markers of 
systemic inflammation.  Four studies13, 14, 16, 17 found statins to improve CRP (p<0.0001, 
p=0.002, p<0.001, and p<0.001, respectively) and three studies showed an improvement 
in ESR (p=0.005, p=0.006, and p<0.001, respectively),13, 14, 16 a decreased incidence of 
swollen joint counts (p=0.0058, p<0.001, and p<0.0001),13, 16, 17 and an improvement in 
tender joint counts (p=0.03, p<0.001, and p<0.05, respectively).14, 16, 17 Only one study17 
showed a decrease in VAS (p<0.001).  Interestingly, while Charles-Schoeman et al13 did 
not demonstrate improvement in the outcomes of interest to systematic review, it did 
demonstrate an improvement in the anti-inflammatory activity of HDL (p=0.026), an 
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outcome not investigated by the other four studies.13, 14, 16, 17  
The results of the studies do not appear dependent upon specific statin 
medications or dosages. Of the studies demonstrating statistically significant 
improvement in DAS28, McCarey et al13 and El-Barbary et al16 used atorvastatin 40mg 
daily, while Maki-Petaja et al14 compared simvastatin 20mg daily and ezetimibe 10mg 
daily. On the other hand, of the two studies showing statistically insignificant 
improvement, Charles-Schoeman et al15 used atorvastatin 80mg daily and Okamoto et 
al17 did not differentiate between statin drugs or dosages.  
Interestingly, differences in DAS outcomes may be related to study quality (see 
Table I).  Those studies that demonstrated a benefit to adjuvant statin use on RA disease 
progression were of higher study quality than those that did not.  The three studies13, 14, 16 
that demonstrate statistically significant improvements in DAS28 are all considered either 
“high” or “moderate” quality.  Given their study design, each study received an initial 
“high quality” rating and after analysis, one remained “high quality” while two were 
subsequently downgraded by one-point to a “moderate quality” rating for potential 
publication bias (financial ties to pharmaceutical industry)13 or an unblinded study 
design.16 The two studies that did not demonstrate such improvement are of lower 
quality.  Charles-Schoeman et al was originally considered “high quality” but was 
downgraded by two-points to a “low quality” rating for indirectness and potential for 
bias.15 Also, due to its study design, Okamoto et al received an initial “low quality” 
rating and was subsequently downgraded to “very low quality” for inconsistency and 
potential publication bias.17 
It does not appear that changes in DAS28 are related to changes in cholesterol 
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levels. Of the four studies13-16 that assessed changes in lipid levels between control and 
intervention groups, all demonstrated statistically significant decreases in total cholesterol 
and LDL with statin use, while only three of the four studies13, 14, 16 demonstrated 
improvements in the DAS28.  
Furthermore, in Maki-Petaja et al,14 ezetimibe (Zetia), a non-statin 
anticholesteremic medication, and simvastatin (Zocor) both demonstrated statistically 
significant decreases in total cholesterol and LDL (p<0.001), however simvastatin 
demonstrated a statistically significant advantage over ezetimibe in decreasing these 
levels (p=0.001). Interestingly, despite the better total cholesterol and LDL-lowering 
profile of simvastatin, both ezetimibe and simvastatin resulted in similar improvements in 
the DAS28 (a statistical difference between drugs of p=0.7). This finding provides 
support to the theory that the decrease in the DAS28 by statin medications is related to 
the anti-inflammatory effects associated with the lowering of LDL, rather than a 
pleiotropic anti-inflammatory effect of statins.  If the former proves true, and the anti-
inflammatory effects are LDL-dependent, it would indicate that any anticholesteremic 
drug could be used to slow disease progression in rheumatoid arthritis.  This finding 
would offer medical providers a greater ability to tailor treatment plans to individual 
patients and would allow those RA patients with contraindications to statins to receive a 
statin-alternative without forgoing anti-inflammatory benefits.  Likewise, it may prompt 
providers to expand the use of hydroxycholorquine, secondary to its possible lipid-
lowering profile,1 and could potentially provide a reduction in current RA therapies and 
their associated ADRs.  
Explanation of Downgrades to Study Quality 
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The GRADE assessment tool10 was used to assess the quality of each study.  Per 
GRADE protocol, the four randomized control trials13-16 reviewed by this systematic 
analysis were given an initial “high” quality rating.  The fifth study17 is an observational 
study, which qualifies it for an initial quality rating of “low”.  Using GRADE criteria, 
review of the studies resulted in a downgrading of study quality for four of the five 
studies13, 15-17 secondary to indirectness, imprecision, and/or bias (see Table I).  
Charles-Schoeman et al15 is considered to have an aspect of indirectness as the 
primary objective of this review, the DAS28, is a secondary outcome in their study, 
resulting in a one-point downgrade in study quality.  The study quality of El-Barbary el 
al16 was also downgraded by one-point, however, this was due to the unblinded nature of 
the study, which results in inherent imprecision. Inconsistency was noted in Okamoto et 
al,17 resulting in a one-point downgrade for prognostically dissimilar groups.  
Another limitation is the risk of publication bias, which is quite high in three of 
the studies13, 15, 17 due to reported conflicts of interest secondary to funding, partnership, 
or association with pharmaceutical companies, resulting in a one-point downgrade in 
study quality.  In what is considered one of the most influential studies demonstrating the 
benefits of statins on RA disease progression, the TARA trial,13 the study is associated 
with Pfizer, the manufacturer of the investigated medication, atorvastatin (Lipitor).   
Furthermore, in Charles-Schoeman el al,15 which assessed impact of statins on high-
sensitivity CRP and inflammatory components of HDL, the principle author is the 
founder of a pharmaceutical company that is developing medications to enhance the anti-
inflammatory properties of HDL, resulting in a significant conflict of interest.  Finally, 
the observational study, Okamoto et al,17 reports substantial conflict of interest, with its 
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authors noting association with 33 pharmaceutical companies. 
The potential for bias in these studies13, 15, 17 calls into question the motives of the 
authors and pharmaceutical companies for writing or sponsoring the studies.  Perhaps the 
motives are based in altruism, however, with Pfizer’s patent in Lipitor ending this year, 
allowing for generic production of atorvastatin, each company may be looking for new 
indications for their anticholesteremic medications in an attempt to extend the sunset 
provisions on their patents.  The motives remain unclear and the bias decreases study 
quality. 
Other Factors Affecting Study Quality 
In addition to the aforementioned downgrades to study criteria, there are other 
limitations to consider which may impact study directness, precision, and consistency 
without being so significant as to qualify the study for further downgrade.  In several 
studies,14-16 sample sizes are small, allowing for imprecision.  Also, Maki-Petaja et al14 
makes no mention as to the packing of the intervention and control medication, calling 
into question the thoroughness of study blinding.  Furthermore, in all studies13-17 patients 
were allowed to change their dose of prednisone or NSAID during course of study, 
however, not all changes were documented, and only one study16 controlled for DMARD 
medications.  Such changes are important to consider as DMARDs, prednisone, and 
NSAIDs directly impact the inflammatory markers used to calculate DAS28, causing an 
overestimation of treatment effect, and leading to imprecision and inconsistency.   
Additionally, several studies13, 15, 17 did not exclude certain patient populations, 
which introduces imprecision and inconsistency into the results.  McCarey et al,13 
Charles-Schoeman et al,15 and Okamoto et al17 included smokers in their study 
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populations, contributing to inherent imprecision, as smoking has been proven to promote 
both an inflammatory and a hypercoaguable state.  Interestingly, only one study, Charles-
Schoeman et al,15 listed concurrent hydroxychloroquine therapy as qualification for study 
exclusion.  As questions remain as to the exact pathophysiology underlying why statins 
decrease inflammation in RA (pleiotropic versus lipid-lowering effects), and in light of 
the potential lipid-lowering effects of hydroxycholorquine,1 the inclusion of patients 
receiving this treatment in the reviewed studies directly impacts results and decreases 
precision and consistency.    
Additionally, while Charles-Schoeman et al15 did not receive a downgrade in 
study quality for aspects listed above, the validity of its results could be called into 
question given that it did not demonstrate a statistically significant improvement in CRP 
with atorvastatin 80mg daily, a finding that is contradictory to the results of the PROVE 
IT-TIMI22 trial.4 The PROVE IT-TIMI22 trial is one of the most prominent trials 
demonstrating the reduction in cardiovascular events with statin therapy;  their 
intervention was atorvastatin 80mg daily.4 
While CRP is not the main outcome assessed by this review, the discrepancy 
between the CRP outcomes of these two studies is important to examine as the 
contradictory findings may be due to study design.  Charles-Schoeman et al15 is a double-
blind randomized controlled study comprised of 20 subjects with rheumatoid arthritis, 11 
of whom received atorvastatin, from one center, UCLA, and all of whom, at baseline, did 
not qualify for lipid-lowering therapy (a specific cholesterol level cut-off was not 
provided). Follow-up for the study was 12 weeks.15 In comparison, the PROVE IT-
TIMI22 trial,4 also a randomized double-blind controlled study, included 4162 subjects, 
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2099 of whom received atorvastatin, from 349 sites in eight countries, and all of whom 
had a total cholesterol of 240mg/dL or less, which, patient-dependent, could qualify them 
for lipid-lowering therapy. Rheumatoid arthritis diagnosis was not considered a 
demographic category. Study follow-up was 18 to 36 months.4 
These two studies4, 15 demonstrate obvious differences in study design; 
differences which could arguably influence CRP results. However, as no other studies 
reviewed in this paper used atorvastatin 80mg as their intervention, it is impossible to 
elucidate if the specific patient population, small study size, single study center, or short 
follow-up period of Charles-Schoeman et al15 contributed to the statistically insignificant 
improvement in DAS28. 
It is also important to consider the subjective nature of the DAS28 itself. While 
this review chose the DAS28 as the primary endpoint to assess RA disease progression, it 
is truly a compilation of several markers of RA disease progression, several of which are 
subjective.  Tender joint counts and VAS are based on patient perception and ESR is 
easily influenced by factors other than inflammation.  Therefore, only swollen joint count 
could be considered an objective marker of inflammation.  While objective, this review 
found swollen joint counts to be an appropriate way to assess RA disease progression as 
swollen joint counts fluctuate variably, making them poor predictor for disease 
progression.  As science progresses and the cellular-level biological processes of RA are 
better understood, a new marker, specific to RA and indicative of RA disease 
progression, may be uncovered, at which time the effectiveness of statins on RA disease 
progression can be screened using this specific, objective marker.  
Recommendations for Further Studies 
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Further studies, including larger, long-term studies, are the next appropriate step 
both to assess the impact of statin medications on RA disease progression, and also to 
differentiate if the effect of statins on DAS28 is LDL-dependent or independent.  Future 
studies should consider the direct impact of DMARDs, prednisone, and NSAIDs on 
systemic inflammatory markers and attempt to control for this imprecision.  It is unethical 
to withhold these treatments from RA patients, so studies should both document dosing 
of these medications and also attempt to improve data precision by providing regimented 
dosing.  Also, should future studies prove statin effects to be LDL-independent, and 
therefore, containing benefits attributable to statin medications alone, further 
investigation must be undertaken to assess if there is a benefit differential between the 
statin classes (hydrophilic or lipophilic) given their different drug profiles.  Similarly, 
should the anti-inflammatory effects of statins prove to be LDL-dependent, non-statin 
anticholesteremic medications and medications with lipid-lowering profiles, such as 
hydroxychloroquine, must be investigated to assess the extent to which these medications 
provide benefit to RA patients.  
In addition to assessing which medications slow RA disease progression, further 
studies should also focus on the cost of RA medications versus the cost of chronic 
disease.  It may be tempting for providers, patients, and insurance companies alike to 
forgo a particular medication due to its monthly cost, however, research may demonstrate 
that the long-term costs related to excluding certain medication from RA therapy, such as 
decreased function and increased number of hospital visits, far outweigh the monthly co-
pay cost of certain medications. 
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CONCLUSION  
It is too early to declare adjuvant statin use to slow RA disease progression, 
however the results of this systematic review are encouraging and demonstrate adjuvant 
statin use in rheumatoid arthritis to have great potential.  Although only three studies13, 14, 
16 demonstrated statin medications to provide a statistically significant decrease the 
DAS28, all five studies13-17 demonstrated their use to improve other markers of systemic 
inflammation.  Application of these results to current clinical practice means, in addition 
to their cardiovascular benefits, statins may allow for decreased traditional RA 
medication use, less ADRs attributable to standard RA therapies, decreases in short-term 
and long-term medical costs, and improvements in daily function and quality of life.  
While further research is necessary, the results are promising and, given the implications, 
may cause a shift in the basics of rheumatoid arthritis treatment.  
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Table I.  Characteristics of Reviewed Studies  
Quality Assessment Summary of Findings 
 Downgrade Criteria 
Quality Importance 
Design Outcomes Limitations Indirectness Imprecision Inconsistency Publication bias likely 
McCarey et al, 200413 
RCT 
Primary: DAS28 
None None No serious imprecision 
No serious 
inconsistency 
Industry 
Funded Moderate High 
Secondary: ESR, CRP, lipid profile, plasma viscosity 
Maki-Petaja et al, 200714 
RCT 
Primary: endothelial function (FMD, aPWV), disease activity (DAS28), 
inflammatory markers (CRP, ESR),  
None None No serious imprecision 
No serious 
inconsistency No High High 
Secondary: lipid profile, blood pressure, tender and swollen joints, 
Charles-Schoeman et al, 200715 
RCT 
Primary: hs-CRP, inflammatory HDL 
None 
DAS28 
considered 
secondary 
outcome 
No serious 
imprecision 
No serious 
inconsistency 
Conflict of 
interest likely Low High Secondary: DAS28, ESR, tender and swollen joints, pain VAS 
El-Barbary et al, 201116 
RCT 
Primary: disease activity (DAS28), lipid profile, cytokines (TNF-α, resistin, 
adiponectin and MDA) and endothelial function (FMD) 
Unblinded None No serious imprecision 
No serious 
inconsistency No Moderate High 
Secondary: tender and swollen joint counts 
Okamoto et al, 200717 
Observational 
Primary: CRP, pain assessment, swollen and tender joint counts, DAS, HAQ 
None None None 
Groups 
prognostically 
dissimilar 
Industry 
Funded Very Low High 
Secondary: ESR, steroid use  
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Table II.  Summary of Findings  
Study Design Intervention Control DAS28* P-value ESR* P-value CRP* P-value 
McCarey et al13 Double-blind randomized 
control trial 
Atorvastatin 
40mg, (n=58) 
Placebo, 
(n=58) 
Mean change [95% CI] Mean change [95% CI] Mean change [95% CI] 
Atorvastatin: -0.50 [(-0.75) – (-0.25)] 
Control: 0.03 [(-0.23) – 0.28] 0.004 
Atorvastatin: -5.03 [(-8.4) – (-1.67)] 
Control: 1.91 [(-1.61) – 5.44] 0.005 
Atorvastatin: -0.46 [(-0.64) – (-0.28)] 
Control: 0.23 [(-0.09) – 0.34] <0.0001 
Maki-Petaja et al14 Double-blind randomized crossover 
trial 
Ezetimibe 
10mg or 
simvastatin 
20mg, (n=20) 
Placebo, 
(n=20) 
Baseline [95% CI]; Post-treatment [95% CI] Baseline [95% CI]; Post-treatment [95% CI] Baseline [95% CI]; Post-treatment [95% CI] 
Simvastatin: 4.65 [2.95 – 8.35];  
                     3.98 [1.36 – 6.6] 
Ezetimibe: 4.41 [2.01 – 6.81];  
                  3.86 [0.72 – 7.0] 
Overall: 
0.002 Simvastatin: 18.6 [(-6.2) – 43.4];  
                     13.8 [(-4.0) – 31.6] 
Ezetimibe: 18.2 [(-13.0) – 49.4];  
                  12.9 [(-6.9) – 32.7]  
Overall: 
0.006 Simvastatin: 15.3 [(-15.1) – 45.7];  
                     10.3 [(-10.5) – 31.1] 
Ezetimibe: 14.2 [(-15.2) – 43.6];  
                   8.8 [(-10.0) – 27.6] 
Overall: 
0.002 
Between 
drugs: 
0.7 
Between 
drugs: 
0.9 
Between 
drugs: 
0.9 
Charles-Schoeman 
et al15 Double-blind randomized control trial Atorvastatin 80mg, (n=9) Placebo, (n=11) Mean change [range of values]
¥
 Mean change [range of values]
¥
 Mean change [range of values]
¥ 
Atorvastatin: -0.80 [(-3.9) – 1.1] 
Control: -0.78 [(-2.5) – 2.2] 0.98 
Atorvastatin: -2.7 [(-28.0) – 14] 
Control: 0 [(-10.0) – 19.0] 0.64 
Atorvastatin: -5.6 [(-24.9) – 1.3] 
Control: 4.8 [(-3.5) – 41.2] 0.14 
El-Barbary et al16 Randomized control trial Atorvastatin 40 mg, (n=15) No statin, (n=15) 
Baseline [95% CI]; Post-treatment [95% CI] Baseline [95% CI]; Post-treatment [95% CI] Baseline [95% CI]; Post-treatment [95% CI] 
Atorvastatin: 6.09 [4.33 – 7.85]; 
                     3.9 [3.0 – 4.8] 
Control: 6.19 [4.55 – 7.83];  
              5.27 [3.95 – 6.59] 
Overall: 
<0.001 Atorvastatin: 58.33 [14.29 – 58.33]; 
                     26.73 [9.61 – 43.85] 
Control: 56.93 [15.31 – 98.55]; 
              43.60 [3.0 – 84.2] 
Overall: 
<0.001 Atorvastatin: 31.46 [2.8 – 60.12]; 
                     7.2 [1.02 – 13.38] 
Control: 33.06 [4.8-61.32]; 
              19.73 [(-1.95) – 41.41] 
Overall: 
<0.001 
Between 
drugs: 
<0.001 
Between 
drugs: 
<0.001 
Between 
drugs: 
<0.001 
Okamoto et al17 Prospective cohort study Statin, (n=279) No statin (n=3873) Mean change [95% CI] Mean change [95% CI] Mean change [95% CI] Statin: 3.45 [1.21 – 5.69] 
No statin: 3.57 [1.09 – 6.05] >0.05 - - 
Statin: 0.85 [-1.87 – 3.57] 
No statin: 1.24 [2.24 – 4.72] <0.0001 
*Where possible, standard deviations were converted to 95% confidence intervals [95% CI] ¥ Study did not provide standard deviations or 95% confidence intervals for results. 
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Figure I.  Flow Diagram of Reviewed Studies 
  
